ALLO-316 produced durable responses (30-40% ORR) in CD70-high ccRCC patients, with certain remissions persisting beyond 12 months and a favorable safety profile characterized by mild CRS and negligible neurotoxicity (NCT04696731). This evidence concerns the gene CD70 and nonpapillary renal cell carcinoma.